Literature DB >> 16670415

How the US drug safety system should be changed.

Brian L Strom1.   

Abstract

Mesh：

Year:  2006        PMID： 16670415     DOI： 10.1001/jama.295.17.2072

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  25 in total

1.  A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.

Authors:  Ben Y Reis; Karen L Olson; Lu Tian; Rhonda L Bohn; John S Brownstein; Peter J Park; Mark J Cziraky; Marcus D Wilson; Kenneth D Mandl
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  Ethical issues in clinical trials involving nanomedicine.

Authors:  David B Resnik; Sally S Tinkle
Journal:  Contemp Clin Trials       Date:  2006-11-17       Impact factor: 2.226

Review 3.  Ethics in nanomedicine.

Authors:  David B Resnik; Sally S Tinkle
Journal:  Nanomedicine (Lond)       Date:  2007-06       Impact factor: 5.307

4.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

5.  Broadening access to electronic healthcare databases.

Authors:  M Soledad Cepeda; Victor S Lobanov; Michael Farnum; Rachel Weinstein; Peter Gates; Dimitris K Agrafiotis; Paul Stang; Jesse A Berlin
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

6.  Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Authors:  Jesse A Berlin; Susan C Glasser; Susan S Ellenberg
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

Review 7.  Pulmonary embolism in a patient taking clozapine.

Authors:  Vinod H Srihari; T Warren Lee
Journal:  BMJ       Date:  2008-06-28

8.  Postmarketing Research and Surveillance: Issues and Challenges.

Authors:  David B Resnik
Journal:  Monitor (Assoc Clin Pharmacol)       Date:  2008-04

9.  National trends in treatment of type 2 diabetes mellitus, 1994-2007.

Authors:  G Caleb Alexander; Niraj L Sehgal; Rachael M Moloney; Randall S Stafford
Journal:  Arch Intern Med       Date:  2008-10-27

10.  Beyond post-marketing research and MedWatch: Long-term studies of drug risks.

Authors:  David B Resnik
Journal:  Drug Des Devel Ther       Date:  2007-10-01       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.